{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T06:18:48Z","timestamp":1782022728832,"version":"3.54.5"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"ADITEC","award":["HEALTH-F4-2011-280873"],"award-info":[{"award-number":["HEALTH-F4-2011-280873"]}]},{"name":"TBVAC2020","award":["643381"],"award-info":[{"award-number":["643381"]}]},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"crossref","award":["060-2009-3"],"award-info":[{"award-number":["060-2009-3"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 105422"],"award-info":[{"award-number":["AI 105422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.addr.2015.11.012","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T01:31:24Z","timestamp":1447810284000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates"],"prefix":"10.1016","volume":"102","author":[{"given":"Else Marie","family":"Agger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2015.11.012_bb0005","series-title":"Global Tuberculosis Report","author":"WHO","year":"2014"},{"key":"10.1016\/j.addr.2015.11.012_bb0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/INF.0b013e3182465be8","article-title":"Commentary: BCG vaccination halves neonatal mortality","volume":"31","author":"Shann","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2015.11.012_bb0015","series-title":"HIV, HCV & TB Pipeline Report","article-title":"The tuberculosis vaccines pipeline: a new path to the same destination?","author":"Frick","year":"2015"},{"key":"10.1016\/j.addr.2015.11.012_bb0020","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2015.11.012_bb0025","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31","volume":"24","author":"Agger","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0030","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.4049\/jimmunol.140.10.3589","article-title":"Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection","volume":"140","author":"Orme","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0035","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1128\/iai.55.9.2037-2041.1987","article-title":"Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells","volume":"55","author":"Muller","year":"1987","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0040","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/IAI.72.3.1608-1617.2004","article-title":"Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines","volume":"72","author":"Holten-Andersen","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0045","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/IAI.68.5.2948-2953.2000","article-title":"CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis","volume":"68","author":"Freidag","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ni.3048","article-title":"The balance between protective and pathogenic immune responses in the TB-infected lung","volume":"16","author":"Orme","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2015.06.001","article-title":"TB vaccines: promoting rapid and durable protection in the lung","volume":"35","author":"Andersen","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0060","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2015.11.012_bb0065","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1086\/315466","article-title":"CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette\u2013Guerin","volume":"181","author":"Feng","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2015.11.012_bb0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/14760584.6.3.441","article-title":"Next generation: tuberculosis vaccines that elicit protective CD8+ T cells","volume":"6","author":"Behar","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2015.11.012_bb0075","doi-asserted-by":"crossref","first-page":"e1004099","DOI":"10.1371\/journal.ppat.1004099","article-title":"Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection","volume":"10","author":"Gopal","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2015.11.012_bb0080","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1128\/IAI.01392-09","article-title":"Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon","volume":"78","author":"Wozniak","year":"2010","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0085","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/mi.2014.136","article-title":"Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge","volume":"8","author":"Monin","year":"2015","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0090","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/infdis\/jiv055","article-title":"Interferon gamma and tumor necrosis factor are not essential parameters of CD4+ T-cell responses for vaccine control of tuberculosis","volume":"212","author":"Orr","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2015.11.012_bb0095","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available","volume":"175","author":"Khader","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0100","first-page":"297","article-title":"Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials","volume":"46","author":"Ribi","year":"1982","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2015.11.012_bb0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1128\/jb.91.3.975-983.1966","article-title":"Effective nonliving vaccine against experimental tuberculosis in mice","volume":"91","author":"Ribi","year":"1966","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2015.11.012_bb0110","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1128\/iai.62.6.2536-2544.1994","article-title":"Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins","volume":"62","author":"Andersen","year":"1994","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0115","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1128\/IAI.66.10.5048-5051.1998","article-title":"Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice","volume":"66","author":"Bosio","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0120","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/IAI.68.2.791-795.2000","article-title":"ESAT-6 subunit vaccination against Mycobacterium tuberculosis","volume":"68","author":"Brandt","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0125","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants","volume":"111","author":"Maisonneuve","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2015.11.012_bb0130","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/cmi.12161","article-title":"Receptor-mediated recognition of mycobacterial pathogens","volume":"15","author":"Killick","year":"2013","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.addr.2015.11.012_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(75)90180-X","article-title":"Biologically active components from mycobacterial cell walls. IV. Protection of mice against aerosol infection with virulent mycobacterium tuberculosis","volume":"16","author":"Ribi","year":"1975","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0140","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1074\/jbc.C200651200","article-title":"Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection","volume":"278","author":"Girardin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2015.11.012_bb0145","doi-asserted-by":"crossref","first-page":"36223","DOI":"10.1074\/jbc.M703079200","article-title":"NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2015.11.012_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20081445","article-title":"Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation","volume":"206","author":"Werninghaus","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2015.11.012_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1128\/jb.100.1.95-102.1969","article-title":"Granuloma formation induced in mice by chemically defined mycobacterial fractions","volume":"100","author":"Bekierkunst","year":"1969","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2015.11.012_bb0160","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ijc.2910240614","article-title":"Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6\u2032-dimycolate) and synthetic analogues","volume":"24","author":"Pimm","year":"1979","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2015.11.012_bb0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/iai.20.1.12-19.1978","article-title":"Nonspecific immunostimulant activities of synthetic trehalose-6,6\u2032-diesters (lower homologs of cord factor)","volume":"20","author":"Parant","year":"1978","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0170","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","article-title":"Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6","volume":"69","author":"Olsen","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0175","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/IAI.72.10.6148-6150.2004","article-title":"Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model","volume":"72","author":"Olsen","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0180","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbamem.2005.10.011","article-title":"Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6\u2032-dibehenate) \u2014 a novel adjuvant inducing both strong CMI and antibody responses","volume":"1718","author":"Davidsen","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2015.11.012_bb0185","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","article-title":"Control of chronic M. tuberculosis infection by CD4 KLRG1-IL-2 secreting memory cells","volume":"190","author":"Lindenstrom","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0190","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","article-title":"Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells","volume":"182","author":"Lindenstrom","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0195","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0200","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1084\/jem.20091750","article-title":"Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle","volume":"206","author":"Ishikawa","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2015.11.012_bb0205","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.0904013","article-title":"Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate","volume":"184","author":"Schoenen","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.immuni.2013.03.010","article-title":"C-type lectin MCL is an FcRgamma-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor","volume":"38","author":"Miyake","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2015.11.012_bb0215","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.4049\/jimmunol.1500102","article-title":"Contribution of MINCLE-SYK Signaling to activation of primary human APCs by mycobacterial cord factor and the novel adjuvant TDB","volume":"195","author":"Ostrop","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0220","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/08923970902824862","article-title":"A synthetic analogue of phosphatidylinositol mannoside is an efficient adjuvant","volume":"31","author":"Denis","year":"2009","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.addr.2015.11.012_bb0225","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1128\/IAI.72.9.5235-5246.2004","article-title":"Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette\u2013Guerin and adjuvant activity in vivo","volume":"72","author":"Sprott","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.vaccine.2011.11.055","article-title":"Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection","volume":"30","author":"Parlane","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0235","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.chembiol.2008.11.008","article-title":"Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells","volume":"16","author":"Layre","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2015.11.012_bb0240","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.182.1.424","article-title":"A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity","volume":"182","author":"Andersen","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0245","doi-asserted-by":"crossref","first-page":"15405","DOI":"10.1074\/jbc.M114.566489","article-title":"Glycerol monomycolate is a novel ligand for the human, but not mouse macrophage inducible C-type lectin, Mincle","volume":"289","author":"Hattori","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2015.11.012_bb0250","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10875-014-0103-7","article-title":"Interaction of pattern recognition receptors with Mycobacterium tuberculosis","volume":"35","author":"Mortaz","year":"2015","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0255","first-page":"423","article-title":"The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection","volume":"84","author":"Cooper","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2015.11.012_bb0260","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2011.07.039","article-title":"Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis","volume":"29","author":"Ballester","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0265","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2567.2007.02597.x","article-title":"Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection","volume":"121","author":"Fonseca","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2015.11.012_bb0270","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1016\/j.vaccine.2012.10.045","article-title":"A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice","volume":"30","author":"Geluk","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0275","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/CVI.00271-15","article-title":"Synthetic long peptide derived from Mycobacterium tuberculosis latency antigen Rv1733c protects against tuberculosis","volume":"22","author":"Coppola","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0280","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1016\/j.vaccine.2006.03.071","article-title":"IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses","volume":"24","author":"Schellack","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0285","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","author":"Lin","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2015.11.012_bb0290","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"van Dissel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0295","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0300","doi-asserted-by":"crossref","first-page":"e114602","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and immunogenicity of H1\/IC31(R), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350cells\/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial","volume":"9","author":"Reither","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0305","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/CVI.00092-15","article-title":"Antiviral innate immune activation in HIV-infected adults negatively affects H1\/IC31-induced vaccine-specific memory CD4+ T Cells","volume":"22","author":"Lenz","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0310","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0315","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0320","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.176.12.7335","article-title":"Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes","volume":"176","author":"Zaks","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0325","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/CVI.00034-08","article-title":"Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone","volume":"15","author":"Wedlock","year":"2008","journal-title":"CVI"},{"key":"10.1016\/j.addr.2015.11.012_bb0330","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1016\/j.vaccine.2014.09.024","article-title":"HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis","volume":"32","author":"Verwaerde","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0335","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.181.3.1849","article-title":"Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation","volume":"181","author":"Shen","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0340","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Garcon","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2015.11.012_bb0345","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0350","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T cell immunity by the novel TB vaccine M72\/AS01 in South African adults","volume":"188","author":"Day","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2015.11.012_bb0355","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0360","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","article-title":"The importance of adjuvant formulation in the development of a tuberculosis vaccine","volume":"188","author":"Baldwin","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0365","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/infdis\/jis425","article-title":"Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment","volume":"207","author":"Coler","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2015.11.012_bb0370","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2015.11.012_bb0375","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0380","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","article-title":"Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis","volume":"172","author":"Orr","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2015.11.012_bb0385","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/jphp.12173","article-title":"Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants","volume":"66","author":"Hussain","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2015.11.012_bb0390","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0395","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0400","first-page":"502","article-title":"Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis","volume":"85","author":"Roberts","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2015.11.012_bb0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2010.03.027","article-title":"Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response","volume":"145","author":"Henriksen-Lacey","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2015.11.012_bb0410","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2009.10.022","article-title":"Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen","volume":"142","author":"Henriksen-Lacey","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2015.11.012_bb0415","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2567.2007.02560.x","article-title":"The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes","volume":"121","author":"Korsholm","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2015.11.012_bb0420","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jconrel.2012.03.016","article-title":"A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog","volume":"160","author":"Christensen","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2015.11.012_bb0425","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.addr.2015.11.012_bb0430","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/infdis\/jiu347","article-title":"Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette\u2013Guerin DeltaureC::hly vaccine's superior protection against tuberculosis","volume":"210","author":"Vogelzang","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2015.11.012_bb0435","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tube.2010.06.002","article-title":"The Achilles heel of BCG","volume":"90","author":"Orme","year":"2010","journal-title":"Tuberculosis (Edinb.)"},{"key":"10.1016\/j.addr.2015.11.012_bb0440","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jac\/dkr588","article-title":"Antiviral applications of Toll-like receptor agonists","volume":"67","author":"Horscroft","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2015.11.012_bb0445","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/eji.200737889","article-title":"Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells","volume":"38","author":"Kamath","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0450","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.vaccine.2010.11.003","article-title":"Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells","volume":"29","author":"Aichinger","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0455","doi-asserted-by":"crossref","first-page":"e5771","DOI":"10.1371\/journal.pone.0005771","article-title":"A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells","volume":"4","author":"Kamath","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0460","doi-asserted-by":"crossref","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2015.11.012_bb0465","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1021\/mp400092y","article-title":"Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization","volume":"10","author":"Primard","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2015.11.012_bb0470","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1182\/blood-2011-07-367615","article-title":"Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity","volume":"118","author":"Tacken","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2015.11.012_bb0480","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1016\/j.vaccine.2013.07.022","article-title":"TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines","volume":"31","author":"Tyne","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0485","doi-asserted-by":"crossref","first-page":"e33555","DOI":"10.1371\/journal.pone.0033555","article-title":"Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates","volume":"7","author":"Spencer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0490","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4161\/hv.23230","article-title":"Novel therapeutic vaccines [(HSP65+IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy","volume":"9","author":"Kita","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2015.11.012_bb0495","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1016\/j.vaccine.2009.01.064","article-title":"Novel prophylactic and therapeutic vaccine against tuberculosis","volume":"27","author":"Okada","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2015.11.012_bb0500","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.tube.2011.10.017","article-title":"Comparing efficacy of BCG\/lactoferrin primary vaccination versus booster regimen","volume":"91","author":"Hwang","year":"2011","journal-title":"Tuberculosis (Edinb.)"},{"key":"10.1016\/j.addr.2015.11.012_bb0505","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.4049\/jimmunol.0900858","article-title":"Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette\u2013Guerin","volume":"183","author":"Venkataswamy","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0510","doi-asserted-by":"crossref","first-page":"e32959","DOI":"10.1371\/journal.pone.0032959","article-title":"Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis","volume":"7","author":"Derrick","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0515","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.4049\/jimmunol.178.6.3721","article-title":"Synergistic effect of Bacillus Calmette Guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection","volume":"178","author":"Dietrich","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0520","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/CVI.00690-12","article-title":"An evaluation of the safety and immunogenicity of a candidate TB vaccine, MVA85A, delivered by aerosol to the lungs of macaques","volume":"20","author":"White","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0525","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1128\/IAI.70.6.3111-3121.2002","article-title":"Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis","volume":"70","author":"Doherty","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0530","doi-asserted-by":"crossref","first-page":"e63344","DOI":"10.1371\/journal.pone.0063344","article-title":"Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice","volume":"8","author":"Todoroff","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0535","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/mi.2013.67","article-title":"Lung niches for the generation and maintenance of tissue-resident memory T cells","volume":"7","author":"Turner","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0540","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.4049\/jimmunol.1400019","article-title":"Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells","volume":"192","author":"Sakai","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0545","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/eji.200940279","article-title":"A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination","volume":"40","author":"Connor","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0550","doi-asserted-by":"crossref","first-page":"e78312","DOI":"10.1371\/journal.pone.0078312","article-title":"Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice","volume":"8","author":"Griffiths","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0555","doi-asserted-by":"crossref","first-page":"e5190","DOI":"10.1371\/journal.pone.0005190","article-title":"Intranasal delivery of cholera toxin induces Th17-dominated T-cell response to bystander antigens","volume":"4","author":"Lee","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0560","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mi.2012.135","article-title":"Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis","volume":"6","author":"Gopal","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0565","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.4049\/jimmunol.177.9.6353","article-title":"Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette\u2013Guerin immunity","volume":"177","author":"Dietrich","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0570","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.11.012_bb0575","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/eji.201343887","article-title":"Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice","volume":"44","author":"Stylianou","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2015.11.012_bb0580","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.vaccine.2009.10.127","article-title":"Mucosal delivery of antigens using adsorption to bacterial spores","volume":"28","author":"Huang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2015.11.012_bb0585","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1128\/IAI.00786-13","article-title":"Mucosal vaccination against tuberculosis using inert bioparticles","volume":"81","author":"Reljic","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2015.11.012_bb0590","doi-asserted-by":"crossref","first-page":"e83884","DOI":"10.1371\/journal.pone.0083884","article-title":"A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93","volume":"9","author":"Orr","year":"2014","journal-title":"PLoS One"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X15002768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X15002768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T22:03:48Z","timestamp":1692137028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X15002768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":117,"alternative-id":["S0169409X15002768"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2015.11.012","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2015.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}